Targeting tumor vasculature with aptamer-functionalized doxorubicin-polylactide nanoconjugates for enhanced cancer therapy

ACS Nano

Volumn 9, Issue 5, 2015, Pages 5072-5081

  Tang, Li ^a   Tong, Rong ^a   Coyle, Virginia J ^b   Yin, Qian ^a   Pondenis, Holly ^b   Borst, Luke B ^c   Cheng, Jianjun ^a   Fan, Timothy M ^b  

^a University of Illinois at Urbana Champaign   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

cancer targeting by aptamer; comparative tumor model; nanoconjugate drug delivery; prostate specific membrane antigen; tumor associated endothelium

Indexed keywords

ANTIGENS; CELL CULTURE; CELL DEATH; CELLS; CYTOLOGY; CYTOTOXICITY; DISEASES; DRUG DOSAGE; MAMMALS; MOBILE SECURITY; NANOCONJUGATES; POLYESTERS; TUMORS; UROLOGY;

APTAMERS; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE; NATURALLY OCCURRING; PROSTATE-SPECIFIC MEMBRANE ANTIGENS; THERAPEUTIC STRATEGY; TUMOR MICROENVIRONMENT; TUMOR MODELS;

ENDOTHELIAL CELLS;

APTAMER; DELAYED RELEASE FORMULATION; DOXORUBICIN; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; NANOCONJUGATE; POLYESTER; POLYLACTIDE;

ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DELAYED RELEASE FORMULATION; DOG; DRUG EFFECTS; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEMANGIOSARCOMA; HUMAN; MALE; METABOLISM; MOUSE; NANOMEDICINE; NEOVASCULARIZATION, PATHOLOGIC; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; TISSUE DISTRIBUTION; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; ANTIGENS, SURFACE; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DOGS; DOXORUBICIN; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATE CARBOXYPEPTIDASE II; HEMANGIOSARCOMA; HUMANS; MALE; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NANOCONJUGATES; NANOMEDICINE; NEOVASCULARIZATION, PATHOLOGIC; POLYESTERS; TISSUE DISTRIBUTION;

EID: 84930221698     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/acsnano.5b00166     Document Type: Article

References (52)

1. Folkman, J. Tumor Angiogenesis: Therapeutic Implications N. Engl. J. Med. 1971, 285, 1182-1186
2. Kerbel, R. S.; Kamen, B. A. The Anti-Angiogenic Basis of Metronomic Chemotherapy Nat. Rev. Cancer 2004, 4, 423-436
3. Nagy, J. A.; Dvorak, H. F. Heterogeneity of the Tumor Vasculature: The Need for New Tumor Blood Vessel Type-Specific Targets Clin. Exp. Metastasis 2012, 29, 657-662
4. Chang, S. S.; OKeefe, D. S.; Bacich, D. J.; Reuter, V. E.; Heston, W. D.; Gaudin, P. B. Prostate-Specific Membrane Antigen Is Produced in Tumor-Associated Neovasculature Clin. Cancer Res. 1999, 5, 2674-2681
5. Chang, S. S.; Reuter, V. E.; Heston, W. D.; Bander, N. H.; Grauer, L. S.; Gaudin, P. B. Five Different Anti-Prostate-Specific Membrane Antigen (PSMA) Antibodies Confirm Psma Expression in Tumor-Associated Neovasculature Cancer Res. 1999, 59, 3192-3198
6. Osborne, J. R.; Akhtar, N. H.; Vallabhajosula, S.; Anand, A.; Deh, K.; Tagawa, S. T. Prostate-Specific Membrane Antigen-Based Imaging Urol. Oncol. 2013, 31, 144-154
7. Milowsky, M. I.; Nanus, D. M.; Kostakoglu, L.; Vallabhajosula, S.; Goldsmith, S. J.; Bander, N. H. Phase I Trial of Yttrium-90-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer J. Clin. Oncol. 2004, 22, 2522-2531
8. Bander, N. H.; Milowsky, M. I.; Nanus, D. M.; Kostakoglu, L.; Vallabhajosula, S.; Goldsmith, S. J. Phase I Trial of 177lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients with Androgen-Independent Prostate Cancer J. Clin. Oncol. 2005, 23, 4591-4601
9. Henry, M. D.; Wen, S.; Silva, M. D.; Chandra, S.; Milton, M.; Worland, P. J. A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody-Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer Cancer Res. 2004, 64, 7995-8001
10. Galsky, M. D.; Eisenberger, M.; Moore-Cooper, S.; Kelly, W. K.; Slovin, S. F.; DeLaCruz, A.; Lee, Y.; Webb, I. J.; Scher, H. I. Phase I Trial of the Prostate-Specific Membrane Antigen-Directed Immunoconjugate Mln2704 in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer J. Clin. Oncol. 2008, 26, 2147-2154
11. Sapra, P.; Shor, B. Monoclonal Antibody-Based Therapies in Cancer: Advances and Challenges Pharmacol. Ther. 2013, 138, 452-469
12. Jayasena, S. D. Aptamers: An Emerging Class of Molecules That Rival Antibodies in Diagnostics Clin. Chem. 1999, 45, 1628-1650
13. Hicke, B. J.; Stephens, A. W. Escort Aptamers: A Delivery Service for Diagnosis and Therapy J. Clin. Invest. 2000, 106, 923-928
14. Farokhzad, O. C.; Cheng, J.; Teply, B. A.; Sherifi, I.; Jon, S.; Kantoff, P. W.; Richie, J. P.; Langer, R. Targeted Nanoparticle-Aptamer Bioconjugates for Cancer Chemotherapy in Vivo Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 6315-6320
15. Shangguan, D.; Li, Y.; Tang, Z.; Cao, Z. C.; Chen, H. W.; Mallikaratchy, P.; Sefah, K.; Yang, C. J.; Tan, W. Aptamers Evolved from Live Cells as Effective Molecular Probes for Cancer Study Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 11838-11843
16. Bates, P. J.; Laber, D. A.; Miller, D. M.; Thomas, S. D.; Trent, J. O. Discovery and Development of the G-Rich Oligonucleotide As1411 as a Novel Treatment for Cancer Exp. Mol. Pathol. 2009, 86, 151-164
17. Mongelard, F.; Bouvet, P. As-1411, a Guanosine-Rich Oligonucleotide Aptamer Targeting Nucleolin for the Potential Treatment of Cancer, Including Acute Myeloid Leukemia Curr. Opin. Mol. Ther. 2010, 12, 107-114
18. Zhong, Y.; Meng, F.; Deng, C.; Zhong, Z. Ligand-Directed Active Tumor-Targeting Polymeric Nanoparticles for Cancer Chemotherapy Biomacromolecules 2014, 15, 1955-1969
19. Gragoudas, E. S.; Adamis, A. P.; Cunningham, E. T., Jr.; Feinsod, M.; Guyer, D. R. Pegaptanib for Neovascular Age-Related Macular Degeneration N. Engl. J. Med. 2004, 351, 2805-2816
20. Barbas, A. S.; Mi, J.; Clary, B. M.; White, R. R. Aptamer Applications for Targeted Cancer Therapy Future Oncol. 2010, 6, 1117-1126
21. Lupold, S. E.; Hicke, B. J.; Lin, Y.; Coffey, D. S. Identification and Characterization of Nuclease-Stabilized RNA Molecules That Bind Human Prostate Cancer Cells via the Prostate-Specific Membrane Antigen Cancer Res. 2002, 62, 4029-4033
22. Cheng, J.; Teply, B. A.; Sherifi, I.; Sung, J.; Luther, G.; Gu, F. X.; Levy-Nissenbaum, E.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. Formulation of Functionalized PLGA-PEG Nanoparticles for in Vivo Targeted Drug Delivery Biomaterials 2007, 28, 869-876
23. Dhar, S.; Kolishetti, N.; Lippard, S. J.; Farokhzad, O. C. Targeted Delivery of a Cisplatin Prodrug for Safer and More Effective Prostate Cancer Therapy in Vivo Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 1850-1855
24. Ni, X.; Zhang, Y.; Ribas, J.; Chowdhury, W. H.; Castanares, M.; Zhang, Z.; Laiho, M.; DeWeese, T. L.; Lupold, S. E. Prostate-Targeted Radiosensitization via Aptamer-Shrna Chimeras in Human Tumor Xenografts J. Clin. Invest. 2011, 121, 2383-2390
25. Yang, J.; Xie, S. X.; Huang, Y.; Ling, M.; Liu, J.; Ran, Y.; Wang, Y.; Thrasher, J. B.; Berkland, C.; Li, B. Prostate-Targeted Biodegradable Nanoparticles Loaded with Androgen Receptor Silencing Constructs Eradicate Xenograft Tumors in Mice Nanomedicine 2012, 7, 1297-1309
26. Tong, R.; Cheng, J. Ring-Opening Polymerization-Mediated Controlled Formulation of Polylactide-Drug Nanoparticles J. Am. Chem. Soc. 2009, 131, 4744-4754
27. Unverferth, D. V.; Magorien, R. D.; Leier, C. V.; Balcerzak, S. P. Doxorubicin Cardiotoxicity Cancer Treat. Rev. 1982, 9, 149-164
28. van Hoesel, Q. G.; Steerenberg, P. A.; Crommelin, D. J.; van Dijk, A.; van Oort, W.; Klein, S.; Douze, J. M.; de Wildt, D. J.; Hillen, F. C. Reduced Cardiotoxicity and Nephrotoxicity with Preservation of Antitumor Activity of Doxorubicin Entrapped in Stable Liposomes in the Lou/M Wsl Rat Cancer Res. 1984, 44, 3698-3705
29. Fosmire, S. P.; Dickerson, E. B.; Scott, A. M.; Bianco, S. R.; Pettengill, M. J.; Meylemans, H.; Padilla, M.; Frazer-Abel, A. A.; Akhtar, N.; Getzy, D. M. et al. Canine Malignant Hemangiosarcoma as a Model of Primitive Angiogenic Endothelium Lab. Invest. 2004, 84, 562-572
30. Liu, T.; Jabbes, M.; Nedrow-Byers, J. R.; Wu, L. Y.; Bryan, J. N.; Berkman, C. E. Detection of Prostate-Specific Membrane Antigen on HUVECs in Response to Breast Tumor-Conditioned Medium Int. J. Oncol. 2011, 38, 1349-1355
31. Chaney, E. J.; Tang, L.; Tong, R.; Cheng, J.; Boppart, S. A. Lymphatic Biodistribution of Polylactide Nanoparticles Mol. Imaging 2010, 9, 153-162
32. Caliceti, P.; Veronese, F. M. Pharmacokinetic and Biodistribution Properties of Poly(Ethylene Glycol)-Protein Conjugates Adv. Drug Delivery Rev. 2003, 55, 1261-1277
33. Chen, A.; Sheu, L. F.; Ho, Y. S.; Lin, Y. F.; Chou, W. Y.; Chou, T. C.; Lee, W. H. Experimental Focal Segmental Glomerulosclerosis in Mice Nephron 1998, 78, 440-452
34. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor Vascular Permeability and the EPR Effect in Macromolecular Therapeutics: A Review J. Controlled Release 2000, 65, 271-284
35. Hobbs, S. K.; Monsky, W. L.; Yuan, F.; Roberts, W. G.; Griffith, L.; Torchilin, V. P.; Jain, R. K. Regulation of Transport Pathways in Tumor Vessels: Role of Tumor Type and Microenvironment Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4607-4612
36. Lamerato-Kozicki, A. R.; Helm, K. M.; Jubala, C. M.; Cutter, G. C.; Modiano, J. F. Canine Hemangiosarcoma Originates from Hematopoietic Precursors with Potential for Endothelial Differentiation Exp. Hematol. 2006, 34, 870-878
37. Tamburini, B. A.; Phang, T. L.; Fosmire, S. P.; Scott, M. C.; Trapp, S. C.; Duckett, M. M.; Robinson, S. R.; Slansky, J. E.; Sharkey, L. C.; Cutter, G. R. et al. Gene Expression Profiling Identifies Inflammation and Angiogenesis as Distinguishing Features of Canine Hemangiosarcoma BMC Cancer 2010, 10, 619
38. Paoloni, M. C.; Tandle, A.; Mazcko, C.; Hanna, E.; Kachala, S.; Leblanc, A.; Newman, S.; Vail, D.; Henry, C.; Thamm, D. et al. Launching a Novel Preclinical Infrastructure: Comparative Oncology Trials Consortium Directed Therapeutic Targeting of Tnfalpha to Cancer Vasculature PLoS One 2009, 4, e4972
39. Kirpotin, D. B.; Drummond, D. C.; Shao, Y.; Shalaby, M. R.; Hong, K.; Nielsen, U. B.; Marks, J. D.; Benz, C. C.; Park, J. W. Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models Cancer Res. 2006, 66, 6732-6740
40. Choi, C. H.; Alabi, C. A.; Webster, P.; Davis, M. E. Mechanism of Active Targeting in Solid Tumors with Transferrin-Containing Gold Nanoparticles Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 1235-1240
41. Tang, L.; Fan, T. M.; Borst, L. B.; Cheng, J. Synthesis and Biological Response of Size-Specific, Monodisperse Drug-Silica Nanoconjugates ACS Nano 2012, 6, 3954-3966
42. Tang, L.; Gabrielson, N. P.; Uckun, F. M.; Fan, T. M.; Cheng, J. Size-Dependent Tumor Penetration and in Vivo Efficacy of Monodisperse Drug-Silica Nanoconjugates Mol. Pharmaceutics 2013, 10, 883-892
43. Tang, L.; Yang, X.; Dobrucki, L. W.; Chaudhury, I.; Yin, Q.; Yao, C.; Lezmi, S.; Helferich, W. G.; Fan, T. M.; Cheng, J. Aptamer-Functionalized, Ultra-Small, Monodisperse Silica Nanoconjugates for Targeted Dual-Modal Imaging of Lymph Nodes with Metastatic Tumors Angew. Chem., Int. Ed. 2012, 51, 12721-12726
44. Injac, R.; Boskovic, M.; Perse, M.; Koprivec-Furlan, E.; Cerar, A.; Djordjevic, A.; Strukelj, B. Acute Doxorubicin Nephrotoxicity in Rats with Malignant Neoplasm Can Be Successfully Treated with Fullerenol C60(OH)24 via Suppression of Oxidative Stress Pharmacol. Rep. 2008, 60, 742-749
45. Abo-Salem, O. M. The Protective Effect of Aminoguanidine on Doxorubicin-Induced Nephropathy in Rats J. Biochem. Mol. Toxicol. 2012, 26, 1-9
46. Meng, H.; Xue, M.; Xia, T.; Ji, Z.; Tarn, D. Y.; Zink, J. I.; Nel, A. E. Use of Size and a Copolymer Design Feature to Improve the Biodistribution and the Enhanced Permeability and Retention Effect of Doxorubicin-Loaded Mesoporous Silica Nanoparticles in a Murine Xenograft Tumor Model ACS Nano 2011, 5, 4131-4144
47. Israeli, R. S.; Powell, C. T.; Corr, J. G.; Fair, W. R.; Heston, W. D. Expression of the Prostate-Specific Membrane Antigen Cancer Res. 1994, 54, 1807-1811
48. Tong, R.; Coyle, V. J.; Tang, L.; Barger, A. M.; Fan, T. M.; Cheng, J. Polylactide Nanoparticles Containing Stably Incorporated Cyanine Dyes for in Vitro and in Vivo Imaging Applications Microsc. Res. Technol. 2010, 73, 901-909
49. Thamm, D. H.; Dickerson, E. B.; Akhtar, N.; Lewis, R.; Auerbach, R.; Helfand, S. C.; MacEwen, E. G. Biological and Molecular Characterization of a Canine Hemangiosarcoma-Derived Cell Line Res. Vet. Sci. 2006, 81, 76-86
50. Akhtar, N.; Padilla, M. L.; Dickerson, E. B.; Steinberg, H.; Breen, M.; Auerbach, R.; Helfand, S. C. Interleukin-12 Inhibits Tumor Growth in a Novel Angiogenesis Canine Hemangiosarcoma Xenograft Model Neoplasia 2004, 6, 106-116
51. Tong, R.; Yala, L.; Fan, T. M.; Cheng, J. The Formulation of Aptamer-Coated Paclitaxel-Polylactide Nanoconjugates and Their Targeting to Cancer Cells Biomaterials 2010, 31, 3043-3053
52. Lee, H.; Berezin, M. Y.; Guo, K.; Kao, J.; Achilefu, S. Near-Infrared Fluorescent pH-Sensitive Probes via Unexpected Barbituric Acid Mediated Synthesis Org. Lett. 2009, 11, 29-32